Coffee Linked to Reduced Recurrence, Death in Late-Stage Colon Cancer

Article

Consumption of four or more cups of coffee a day was associated with a reduced risk for colon cancer recurrence and death in patients with stage III disease.

Image © Valentyn Volkov / Shutterstock.com

Consumption of four or more cups of coffee a day was associated with a reduced risk for colon cancer recurrence and death in a group of patients with stage III disease, a new study has found.

In addition, researchers led by Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, reported increased coffee intake was also associated with improved disease-free, recurrence-free, and overall survival, and that these associations occurred independently of other predictors of outcome, diet, and lifestyle factors.

“Although our observational study does not offer conclusive evidence for causality, our findings potentially inform colon cancer biology and offer further insight into the role of diet and lifestyle in outcome for patients with colon cancer. Further studies are needed to confirm our findings,” Fuchs and colleagues wrote in the Journal of Clinical Oncology.

For the study, Fuchs and colleagues evaluated prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherbal tea taken from 953 patients with stage III colon cancer during and 6 months after adjuvant chemotherapy.

“We hypothesized that coffee might reduce colon cancer recurrence through improved insulin sensitization and decreased hyperinsulinemia, on the basis of previous studies supporting the role of high-energy balance states in promoting colon cancer recurrence and mortality and studies demonstrating an inverse relationship between coffee consumption and risk of type 2 diabetes,” the researchers wrote.

During the study period, 329 patients had cancer recurrence or new primary tumors and 288 patients died. Results of the analysis showed that consumption of four or more cups of caffeinated coffee a day reduced recurrence and mortality by almost half compared with never consuming coffee (hazard ratio [HR], 0.58 [95% confidence interval (CI), 0.34–0.99]; P for trend = .002) and compared with abstaining from coffee (HR, 0.48 [95% CI, 0.25–0.91]; P for trend = .002).

“Increasing total coffee intake was also associated with a significant improvement in overall survival (P for trend = .008) and a trend toward improved recurrence-free survival that did not reach statistical significance (P for trend = .06),” the researchers wrote. “These results were largely unchanged when further adjusted for sugar-sweetened beverage intake and glycemic load (disease-free survival, P for trend = .002; recurrence-free survival, P for trend = .07; overall survival, P for trend = .01).”

The researchers noted that they cannot rule out the possibility that the association seen between coffee consumption and improved disease-free survival resulted from confounding variables. However, analyses showed that these associations persisted even after they adjusted for physical activity, dietary glycemic load, sugar-sweetened beverage intake, and Western and prudent dietary patterns.

No link with improved survival outcomes was found for decaffeinated coffee or nonherbal tea.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Related Content